Vantas^® (histrelin), implant

• For the treatment of advanced prostate cancer with histrelin, a (luteinizing hormone-releasing hormone (LHRH) agonist
• The implant is placed in the patient’s arm for 12 months.
• Product information based on national marketing authorisations is available by request

www.vantas.eu (for patients and healthcare professionals)

Vantas is marketed by Orion under license from Endo Pharmaceuticals, USA

Enanton^® (leuprolide acetate), injection

• For the palliative treatment of prostate cancer
• An LHRH analogue available in injectable formulations for treatment intervals of 1, 3 and 6 months.
• Product information based on national marketing authorisations is available by request

 Enanton is marketed by Orion under license from Takeda, Japan

Kentera® (oxybutynin)

• A transdermal patch formulation of oxybutynin, applied twice weekly.
• For the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with unstable bladder
• Hitherto the only non-orally administered product approved for overactive bladder (OAB)
• Product information based on national marketing authoristaions is provided by request 

Kentera is marketed by Orion in the Nordic countries, Switzerland and the UK, under license from Recordati, Italy.